ChemoCentryx drug meets main goal in mid-stage study

January 6, 2016 12:26 PM

28 0

ChemoCentryx Inc said its experimental drug was as effective as standard of care in treating patients with a rare type of autoimmune disease in a mid-stage study, sending its shares up 11.3 percent in light premarket trading.

The drug, CCX168, was tested in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, or AAV, a type of rare autoimmune inflammation of blood vessels that affects about 40,000 people in the United States.

Read more

To category page